成大生物：子公司流感病毒裂解疫苗（高剂量）获临床试验批准

Core Viewpoint - Chengda Bio announced that its wholly-owned subsidiary, Chengda Bio (Benxi) Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a high-dose influenza virus split vaccine [1] Group 1: Clinical Trial Approval - The clinical trial approval notification number is 2026LP00405 [1] - The high-dose influenza virus split vaccine is developed using influenza virus strains recommended by the World Health Organization (WHO) [1] - The effective component of the vaccine is four times the dosage of the conventional influenza vaccine [1]